Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Resistant mechanisms to BRAF inhibitors in melanoma.

Manzano JL, Layos L, Bugés C, de Los Llanos Gil M, Vila L, Martínez-Balibrea E, Martínez-Cardús A.

Ann Transl Med. 2016 Jun;4(12):237. doi: 10.21037/atm.2016.06.07. Review.

2.

Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment.

Yeh I.

F1000Res. 2016 Jun 28;5. pii: F1000 Faculty Rev-1529. doi: 10.12688/f1000research.8247.1. eCollection 2016. Review.

3.

Animal Models of Uveal Melanoma: Methods, Applicability, and Limitations.

Stei MM, Loeffler KU, Holz FG, Herwig MC.

Biomed Res Int. 2016;2016:4521807. doi: 10.1155/2016/4521807. Epub 2016 Jun 6. Review.

4.

YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.

Lyubasyuk V, Ouyang H, Yu FX, Guan KL, Zhang K.

Mol Cell Oncol. 2014 Dec 1;2(1):e970957. doi: 10.4161/23723548.2014.970957. eCollection 2015 Jan-Mar.

5.

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA.

Oncologist. 2016 Jul;21(7):848-54. doi: 10.1634/theoncologist.2015-0522. Epub 2016 Jun 10.

PMID:
27286787
6.

Uveal melanoma as a target for immune-therapy.

Oliva M, Rullan AJ, Piulats JM.

Ann Transl Med. 2016 May;4(9):172. doi: 10.21037/atm.2016.05.04. Review.

7.

Investigation of Somatic GNAQ, GNA11, BAP1 and SF3B1 Mutations in Ophthalmic Melanocytomas.

Francis JH, Wiesner T, Milman T, Won HH, Lin A, Lee V, Albert DM, Folberg R, Berger MF, Char DH, Marr B, Abramson DH.

Ocul Oncol Pathol. 2016 Apr;2(3):171-7. doi: 10.1159/000442352. Epub 2016 Jan 27.

8.

Adjuvant Therapy of Uveal Melanoma: Current Status.

Triozzi PL, Singh AD.

Ocul Oncol Pathol. 2014 Oct;1(1):54-62. doi: 10.1159/000367715. Epub 2014 Sep 10. Review.

9.

Animal Eye Models for Uveal Melanoma.

Cao J, Jager MJ.

Ocul Oncol Pathol. 2015 Apr;1(3):141-50. doi: 10.1159/000370152. Epub 2015 Apr 9. Review.

10.

Uveal Melanoma Patient-Derived Xenografts.

Carita G, Némati F, Decaudin D.

Ocul Oncol Pathol. 2015 Apr;1(3):161-9. doi: 10.1159/000370154. Epub 2015 Apr 9. Review.

11.

Drosophila as a Potential Model for Ocular Tumors.

Bennett D, Lyulcheva E, Cobbe N.

Ocul Oncol Pathol. 2015 Apr;1(3):190-9. doi: 10.1159/000370155. Epub 2015 Apr 9. Review.

12.

Bilateral Diffuse Uveal Melanocytic Proliferation: Molecular Genetic Analysis of a Case and Review of the Literature.

Mittal R, Cherepanoff S, Thornton S, Kalirai H, Damato B, Coupland SE.

Ocul Oncol Pathol. 2015 Dec;2(2):94-9. doi: 10.1159/000440766. Epub 2015 Oct 1.

13.

Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.

Urtatiz O, Van Raamsdonk CD.

Front Genet. 2016 Apr 20;7:59. doi: 10.3389/fgene.2016.00059. eCollection 2016.

14.

A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents.

Collins DC, Yela R, Horgan N, Power DG.

Case Rep Oncol Med. 2016;2016:6564094. doi: 10.1155/2016/6564094. Epub 2016 Mar 24.

15.

Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma.

Ayturk UM, Couto JA, Hann S, Mulliken JB, Williams KL, Huang AY, Fishman SJ, Boyd TK, Kozakewich HP, Bischoff J, Greene AK, Warman ML.

Am J Hum Genet. 2016 Apr 7;98(4):789-95. doi: 10.1016/j.ajhg.2016.03.009.

PMID:
27058448
16.

Novel Insights into the Role of Long Noncoding RNA in Ocular Diseases.

Li F, Wen X, Zhang H, Fan X.

Int J Mol Sci. 2016 Mar 31;17(4). pii: E478. doi: 10.3390/ijms17040478. Review.

17.

Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.

Wiesner T, Kutzner H, Cerroni L, Mihm MC Jr, Busam KJ, Murali R.

Pathology. 2016 Feb;48(2):113-31. doi: 10.1016/j.pathol.2015.12.007. Epub 2016 Jan 18.

PMID:
27020384
18.

Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein α-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders.

Babinsky VN, Hannan FM, Gorvin CM, Howles SA, Nesbit MA, Rust N, Hanyaloglu AC, Hu J, Spiegel AM, Thakker RV.

J Biol Chem. 2016 May 13;291(20):10876-85. doi: 10.1074/jbc.M115.696401. Epub 2016 Mar 18.

19.
20.

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW.

Clin Cancer Res. 2016 Mar 1;22(5):1234-42. doi: 10.1158/1078-0432.CCR-15-2071.

PMID:
26933176
Items per page

Supplemental Content

Write to the Help Desk